Investigation of the Lobular Carcinoma in Situ, Using Molecular Genetic Techniques, for the Involvement of Novel Genes
Abstract
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), i.e. lobular neoplasia (LN), are lesions of significance in terms of risk to the patient in the development of invasive carcinoma. A correlation between the lobular histological type and inactivation of E-cadherin, a cell adhesion protein, has been reported. As well, mutations in CDH1 have been reported in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC. Our study proposes to investigate LN lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins with the goal of characterizing a molecular genetic profile. We have accrued 36 cases containing ALH/LCIS without adjacent invasive carcinoma. Previous studies have found negative E- cadherin, beta- and alpha-catenin protein expression in these lesions. Moreover, LCIS but not ALH cases were characterized by mutations and LOH at 16q was found to be an infrequent event. Recent studies have also demonstrated cytoplasmic (rather than membrane) localization of p120-catenin in LN lesions. As a mechanism for the inactivation of E- cadherin has yet to be elucidated in LN, we have used CGH micraarrays to study 12 ALH and 14 LCIS lesions. Following validation by Real Time PCR it will be possible to describe events occurring at the earliest stages of breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2005
- Accession Number
- ADA437874
Entities
People
- Irene L. Andrulis
- Teresa L. Mastracci
Organizations
- Mount Sinai Hospital, Toronto